PE20091526A1 - Derivados del acido fenilacetico como moduladores de la inflamacion - Google Patents

Derivados del acido fenilacetico como moduladores de la inflamacion

Info

Publication number
PE20091526A1
PE20091526A1 PE2008002152A PE2008002152A PE20091526A1 PE 20091526 A1 PE20091526 A1 PE 20091526A1 PE 2008002152 A PE2008002152 A PE 2008002152A PE 2008002152 A PE2008002152 A PE 2008002152A PE 20091526 A1 PE20091526 A1 PE 20091526A1
Authority
PE
Peru
Prior art keywords
derivatives
modulators
inflammation
acid
phenylacetic acid
Prior art date
Application number
PE2008002152A
Other languages
English (en)
Inventor
Mark Grillo
An-Rong Li
Jiwen Liu
Julio C Medina
Yongli Su
Yingcai Wang
Janan Jona
Alan Allgeier
Jacqueline Milne
Jerry Murry
Joseph F Payack
Thomas Storz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20091526A1 publication Critical patent/PE20091526A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

REFIERE A DERIVADOS DEL ACIDO FENILACETICO DE FORMULA (I), DONDE R1 ES ALQUILO C1-8 O CICLOALQUILO C1-8; R2 ES HALO, ALQUILO C1-8, HALOALCOXI C1-8, ENTRE OTROS; X ES CLORO O FLUOR. SON COMPUESTOS PREFERIDOS: ACIDO 2-(4-(4-(TER-BUTILCARBAMOIL)-2-(2-CLORO-4-CICLOPROPILFENILSULFONAMIDO)FENOXI)-2,5-DIFLUOROFENIL)ACETICO, ACIDO 2-(4-(4-(TERBUTILCARBAMOIL)-2-(2-CLORO-4-(TRIFLUOROMETOXI)FENILSULFONAMIDO)FENOXI)-5-CLORO-2-FLUOROFENIL)ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION DE UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. DICHOS COMPUESTOS MODULAN EL CRTH2 Y/O UNO DE OTROS RECEPTORES DE LA PGD2, SIENDO DE UTILIDAD EN EL TRATAMIENTO DEL ASMA, RINITIS ALERGICA, ECZEMA, SORIASIS, ENTRE OTROS
PE2008002152A 2007-12-19 2008-12-19 Derivados del acido fenilacetico como moduladores de la inflamacion PE20091526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US843307P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
PE20091526A1 true PE20091526A1 (es) 2009-11-01

Family

ID=40564868

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002152A PE20091526A1 (es) 2007-12-19 2008-12-19 Derivados del acido fenilacetico como moduladores de la inflamacion

Country Status (20)

Country Link
US (1) US8183293B2 (es)
EP (1) EP2231595B1 (es)
JP (1) JP5437267B2 (es)
KR (1) KR20100102668A (es)
CN (1) CN101903338A (es)
AR (1) AR071279A1 (es)
AU (1) AU2008343924B2 (es)
BR (1) BRPI0821197A2 (es)
CA (1) CA2707789A1 (es)
CL (1) CL2008003832A1 (es)
CO (1) CO6321234A2 (es)
CR (1) CR11572A (es)
EA (1) EA201001029A1 (es)
ES (1) ES2471919T3 (es)
IL (1) IL206069A0 (es)
MA (1) MA32013B1 (es)
PE (1) PE20091526A1 (es)
TN (1) TN2010000223A1 (es)
TW (1) TW200940051A (es)
WO (1) WO2009085177A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
BR112014014558A8 (pt) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
HRP20211960T1 (hr) 2016-03-22 2022-03-18 Merck Sharp & Dohme Corp. Alosterični modulatori nikotinskih acetilcolinskih receptora
EP3424927B1 (en) * 2017-07-04 2019-04-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704158D0 (en) 1987-02-23 1987-04-01 Wellcome Found Substituted hydantoin compounds
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5776951A (en) 1993-06-30 1998-07-07 Glaxo Wellcome Inc. Anti-atherosclerotic diaryl compounds
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
CA2208011A1 (en) * 1994-12-20 1996-06-27 F. Hoffmann-La Roche Ag Aryl-and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CA2264521A1 (en) 1996-09-12 1998-03-19 Schering Aktiengesellschaft Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JPH11202458A (ja) 1998-01-16 1999-07-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
CA2363145C (en) 1999-03-01 2006-02-14 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
DE60020226T2 (de) 1999-03-10 2006-02-02 Shionogi & Co., Ltd. Medizinische zubereitungen mit [2.2.1] und [3.1.1]bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind
ATE315230T1 (de) 1999-08-23 2006-02-15 Bml Inc Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US20020072530A1 (en) 2000-02-01 2002-06-13 Bing-Yan Zhu Indole and benzimidazole inhibitors of factor Xa
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
EP1295872A4 (en) 2000-06-02 2007-05-16 Shionogi & Co ANTAGONIST MEDICINAL PRODUCT FOR PGD2 / TXA2 RECEPTORS
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2002229611A1 (en) 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
NZ535309A (en) 2002-03-19 2006-05-26 Ono Pharmaceutical Co Carboxylic acid compounds and drugs containing the compounds as the active ingredient
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
BR0317591A (pt) * 2002-12-20 2005-11-22 Amgen Inc Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
US8148572B2 (en) * 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
BRPI0720254A2 (pt) * 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
JP2013500979A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの皮膚用製剤

Also Published As

Publication number Publication date
AU2008343924A2 (en) 2011-02-17
TN2010000223A1 (en) 2011-11-11
AU2008343924B2 (en) 2013-01-17
CR11572A (es) 2010-08-13
JP2011507847A (ja) 2011-03-10
AU2008343924A1 (en) 2009-07-09
JP5437267B2 (ja) 2014-03-12
AR071279A1 (es) 2010-06-09
EA201001029A1 (ru) 2011-06-30
EP2231595A1 (en) 2010-09-29
CA2707789A1 (en) 2009-07-09
WO2009085177A1 (en) 2009-07-09
MA32013B1 (fr) 2011-01-03
CL2008003832A1 (es) 2010-03-26
CN101903338A (zh) 2010-12-01
KR20100102668A (ko) 2010-09-24
ES2471919T3 (es) 2014-06-27
EP2231595B1 (en) 2014-04-23
TW200940051A (en) 2009-10-01
US8183293B2 (en) 2012-05-22
BRPI0821197A2 (pt) 2015-06-16
CO6321234A2 (es) 2011-09-20
IL206069A0 (en) 2010-11-30
US20090275659A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
PE20091526A1 (es) Derivados del acido fenilacetico como moduladores de la inflamacion
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
PE20131047A1 (es) Compuestos heterociclicos moduladores del acido urico
EA201001554A1 (ru) Ингибиторы модуляторов воспаления: производные олеанолевой кислоты, гомологированные с-17
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
PE20160838A1 (es) Procedimiento para la preparacion de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carboxamida, sus sales y su monohidrato
PE20141322A1 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
PE20120055A1 (es) (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
PE20161243A1 (es) Compuesto heterociclico fusionado
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
BR112014009102A2 (pt) compostos químicos
PE20131117A1 (es) Derivados de bencimidazol como inhibidores de prostaglandinas
PE20110136A1 (es) Compuestos organicos
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
AR054118A1 (es) Amidas de acido pirazolcarboxilico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FD Application declared void or lapsed